Access cutting-edge primary central nervous system lymphoma treatment through this clinical trial at a research site in Palo Alto. Study-provided care at no cost to qualified participants.
Access primary central nervous system lymphoma specialists in Palo Alto at no cost
This study follows strict safety protocols and ethical guidelines
All study-related primary central nervous system lymphoma treatment provided free
This study will evaluate the efficacy, safety, and pharmacokinetics of tirabrutinib monotherapy in patients with relapsed or refractory PCNSL (Part A), and tirabrutinib in combination with one of two different high dose methotrexate based regimens (methotrexate/ temozolomide/rituximab or rituximab/methotrexate/procarbazine/ vincristine) as first line therapy in patients with newly diagnosed, treatment naïve PCNSL (Part B)
Sponsor: Ono Pharmaceutical Co. Ltd
Check if you qualify for this primary central nervous system lymphoma clinical trial in Palo Alto, CA
If you're searching for primary central nervous system lymphoma treatment options in Palo Alto, CA, this clinical trial may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Palo Alto research site is actively enrolling participants for this clinical trial. You'll receive care from experienced primary central nervous system lymphoma specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.